Indo US Bio-Tech Ltd. (INDOUS) AI Stock Analysis

0 Followers

Indo US Bio-Tech Ltd.

(NSE:INDOUS)

Select Model

Rating:55Neutral

Price Target:INR 68.00▲(2.87% Upside)

Action:reiterated

Date:10/30/26

The overall score of 55 reflects a balance of strengths and risks. The company's solid balance sheet and low valuation are positive, but these are offset by significant negative cash flows and a bearish technical trend. The weak cash generation is the primary concern, as it pressures liquidity and earnings quality despite decent profitability.

Positive Factors

Integrated seed platformThe company operates across the seed value chain, from R&D and breeding through production, processing, branding and distribution. This integrated model can support product differentiation, farmer reach and control over commercialization, providing a durable platform for building market presence.

Negative Factors

Negative cash generationNegative operating and free cash flow show that reported earnings were not converted into cash during FY2026. Continued weak cash conversion can restrict funding for seed development and working needs, while increasing dependence on borrowing or other external sources of liquidity.

Indo US Bio-Tech Ltd. (INDOUS) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 1.59B
Dividend Yield: ―
Average Volume (3M): 2,494
Price to Earnings (P/E): 31.2
Beta (1Y): 0.74
Revenue Growth: -18.31%
EPS Growth: -74.34%
Country: India
Employees: 883
Sector: General
Sector Strength: 55
Industry: Agricultural Inputs

Indo US Bio-Tech Ltd. Business Overview & Revenue Model

Company Description

Indo Us Bio-Tech Ltd. is an Indian firm specializing in the entire seed value chain, encompassing production, processing, packaging, and distribution across India. Their diverse product lineup features an extensive selection of vegetable seeds, inclu...

How the Company Makes Money

Indo US Bio-Tech Ltd. primarily makes money by selling agricultural seeds to farmers, distributors, and other agri-channel partners. Its main revenue stream is the sale of seeds produced through its integrated pipeline: (1) developing seed varieties/...

Indo US Bio-Tech Ltd. Financial Statement Overview

Summary

Mixed financials: Solid balance sheet with low leverage (D/E 0.40) and healthy ROE (14.2%), but weak cash flow generation with negative operating and free cash flow, raising liquidity concerns. Income statement shows decent operating improvement but net income declined due to higher interest costs.

Income Statement

65Positive

Balance Sheet

80Positive

Cash Flow

20Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2025	Mar 2024
Income Statement
Total Revenue	642.31M	1.10B	1.04B
Gross Profit	143.60M	301.69M	294.70M
EBITDA	88.39M	170.66M	13.08M
Net Income	71.37M	131.23M	162.67M
Balance Sheet
Total Assets	1.17B	1.33B	978.43M
Cash, Cash Equivalents and Short-Term Investments	5.88M	69.13M	2.48M
Total Debt	276.43M	370.36M	148.36M
Total Liabilities	305.44M	405.63M	193.24M
Stockholders Equity	866.69M	925.34M	785.18M
Cash Flow
Free Cash Flow	-83.36M	-149.89M	-100.69K
Operating Cash Flow	-74.56M	-125.81M	91
Investing Cash Flow	-34.90M	-15.00M	-7.92M
Financing Cash Flow	104.92M	199.56M	-14.77M

Indo US Bio-Tech Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price66.10

Price Trends

50DMA74.23Negative

100DMA79.81Negative

200DMA95.62Negative

Market Momentum

MACD-2.56Positive

RSI40.97Neutral

STOCH7.91Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDOUS, the sentiment is Negative. The current price of 66.10 is below the 20-day moving average (MA) of 69.67, below the 50-day MA of 74.23, and below the 200-day MA of 95.62, indicating a bearish trend. The MACD of -2.56 indicates Positive momentum. The RSI at 40.97 is Neutral, neither overbought nor oversold. The STOCH value of 7.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:INDOUS.

Indo US Bio-Tech Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:INDOUS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:NATHBIOGEN	66Neutral	INR 2.66B	7.65	―	1.43%	21.02%	-3.13%
IN:IPL	60Neutral	INR 13.94B	12.72	―	0.63%	2.89%	-9.47%
IN:IGCL	56Neutral	INR 3.85B	8.41	―	―	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:INDOUS	55Neutral	INR 1.32B	31.19	―	―	-18.31%	-74.34%
IN:BESTAGRO	48Neutral	INR 5.45B	11.34	―	0.65%	-19.67%	275.98%
IN:ASTEC	42Neutral	INR 11.96B	-15.04	―	―	16.06%	36.97%

* General Sector Average

Performance Comparison

IN:INDOUS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:INDOUS	Indo US Bio-Tech Ltd.	66.10	-57.80	-46.65%
IN:ASTEC	Astec Lifesciences Limited	553.45	-82.55	-12.98%
IN:BESTAGRO	Best Agrolife Ltd.	15.21	-5.04	-24.88%
IN:IPL	India Pesticides Ltd.	119.20	-59.68	-33.37%
IN:NATHBIOGEN	Nath Bio-Genes (India) Ltd.	142.45	-21.33	-13.02%
IN:IGCL	Indogulf Cropsciences Limited	61.62	-37.43	-37.79%

Indo US Bio-Tech Ltd. Corporate Events

Indo US Bio-Tech Sets Virtual Date for 22nd Annual General Meeting

Sep 6, 2026

Indo US Bio-Tech Ltd. has announced that its 22nd Annual General Meeting will be held on September 30, 2026 at 2:30 p.m. via video conferencing and other audio-visual means, in line with recent circulars issued by the Ministry of Corporate Affairs an...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026

Indo US Bio-Tech Ltd. AI Stock Analysis